{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"BIO","limit":50},"count":50,"signals":[{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":76,"context":"ees | 244,000 | 22,000 | | Advisory (Non-Binding) Vote to Approve Executive Compensation (page 19)We are asking our stockholders to cast a non-binding advisory vote to approve the compensation of our named executive officers.Approval of the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan (page 20)We are asking our stockholders to approve the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan to (i","filed_date":"2026-03-25","accession":"0000012208-26-000020","full_text":"https://origin.rootz.global/static/filing/0000012208-26-000020.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":65,"context":"reimbursement for our products or diagnostic tests using our products, or a decision by a third-party payor to not cover our products could reduce or eliminate utilization of our products and have a material adverse effect on our sales, results of operations and financial condition. In addition, healthcare reform measures have been and will be adopted in the future, any of which could limit the amounts that governments","filed_date":"2026-02-13","accession":"0000012208-26-000010","full_text":"https://origin.rootz.global/static/filing/0000012208-26-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ng positions on a quarterly basis.24We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2025-10-29","accession":"0000012208-25-000077","full_text":"https://origin.rootz.global/static/filing/0000012208-25-000077.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ng positions on a quarterly basis.22We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2025-07-31","accession":"0000012208-25-000052","full_text":"https://origin.rootz.global/static/filing/0000012208-25-000052.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ng positions on a quarterly basis.21We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2025-05-01","accession":"0000012208-25-000026","full_text":"https://origin.rootz.global/static/filing/0000012208-25-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":75,"context":"that provides for severance or termination payments with an estimated value exceeding 2.99 times the sum of the executives base salary plus target short-term bonus. This proposal only applies to the Named Executive Officers. This provision shall at least be included in the Governess Guidelines of the Company. Severance or termination payments include cash, equity or other pay that is paid out or vests due to a senior e","filed_date":"2025-03-26","accession":"0001308179-25-000235","full_text":"https://origin.rootz.global/static/filing/0001308179-25-000235.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":65,"context":"reimbursement for our products or diagnostic tests using our products, or a decision by a third-party payor to not cover our products could reduce or eliminate utilization of our products and have a material adverse effect on our sales, results of operations and financial condition. In addition, healthcare reform measures have been and will be adopted in the future, any of which could limit the amounts that governments","filed_date":"2025-02-14","accession":"0000012208-25-000007","full_text":"https://origin.rootz.global/static/filing/0000012208-25-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ling positions on a quarterly basis.We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2024-10-31","accession":"0000012208-24-000063","full_text":"https://origin.rootz.global/static/filing/0000012208-24-000063.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":13,"context":"surance regarding the ultimate outcome of these matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period. 13. RESTRUCTURING COSTSIn February 2021, we announced a strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacted our operations in","filed_date":"2024-08-02","accession":"0000012208-24-000052","full_text":"https://origin.rootz.global/static/filing/0000012208-24-000052.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ling positions on a quarterly basis.We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2024-08-02","accession":"0000012208-24-000052","full_text":"https://origin.rootz.global/static/filing/0000012208-24-000052.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ling positions on a quarterly basis.We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2024-05-08","accession":"0000012208-24-000039","full_text":"https://origin.rootz.global/static/filing/0000012208-24-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":77,"context":"future benefits that will be received by participants other than pursuant to the director compensation policy. |  Name and Position |  |  Dollar Value of RSUs ($)(1) |  |  Number of Shares (#) | | |  Named Executive Officers: |  |  |  |  | | |  Norman Schwartz |  |  |  |  | | |  President, Chief Executive Officer and Chairman of the Board |  |  |  |  | | |  Ilan Daskal(3) |  |  |  |  | | |  Former Executive Vice Preside","filed_date":"2024-03-27","accession":"0001308179-24-000313","full_text":"https://origin.rootz.global/static/filing/0001308179-24-000313.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":64,"context":"reimbursement for our products or diagnostic tests using our products, or a decision by a third-party payor to not cover our products could reduce or eliminate utilization of our products and have a material adverse effect on our sales, results of operations and financial condition. In addition, healthcare reform measures have been and will be adopted in the future, any of which could limit the amounts that governments","filed_date":"2024-02-16","accession":"0000012208-24-000013","full_text":"https://origin.rootz.global/static/filing/0000012208-24-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":29,"context":".24(B) hereof. Loan Modification Offer is defined in Section 2.24(A) hereof. Loan Parties means each Borrower and each Guarantor. Margin Stock shall have the meaning assigned thereto in Regulation U. Material Adverse Effect means a material adverse effect on (i) the business, Property, financial condition or results of operations of the Borrowers and their Subsidiaries taken as a whole, (ii) the ability of the Borrowers","filed_date":"2024-02-14","accession":"0000012208-24-000005","full_text":"https://origin.rootz.global/static/filing/0000012208-24-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2023-10-27","accession":"0000012208-23-000072","full_text":"https://origin.rootz.global/static/filing/0000012208-23-000072.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":16,"context":"ing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2023-08-04","accession":"0000012208-23-000063","full_text":"https://origin.rootz.global/static/filing/0000012208-23-000063.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":16,"context":"ing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2023-05-05","accession":"0000012208-23-000047","full_text":"https://origin.rootz.global/static/filing/0000012208-23-000047.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":76,"context":"00 |  |  18,000 |  | #### Advisory (Non-Binding) Vote to Approve Executive Compensation (page 20) We are asking our stockholders to cast a non-binding advisory vote to approve the compensation of our named executive officers. #### Advisory (Non-Binding) Vote on the Frequency of Future Advisory Votes to Approve Executive Compensation Every 1, 2 or 3 Years (page 21) We are asking our stockholders to cast a non-binding adv","filed_date":"2023-03-29","accession":"0001308179-23-000427","full_text":"https://origin.rootz.global/static/filing/0001308179-23-000427.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":21,"context":"reimbursement for our products or diagnostic tests using our products, or a decision by a third-party payor to not cover our products could reduce or eliminate utilization of our products and have a material adverse effect on our sales, results of operations and financial condition. In addition, healthcare reform measures have been and will be adopted in the future, any of which could limit the amounts that governments","filed_date":"2023-02-17","accession":"0000012208-23-000031","full_text":"https://origin.rootz.global/static/filing/0000012208-23-000031.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2022-10-28","accession":"0000012208-22-000071","full_text":"https://origin.rootz.global/static/filing/0000012208-22-000071.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2022-07-29","accession":"0000012208-22-000046","full_text":"https://origin.rootz.global/static/filing/0000012208-22-000046.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2022-04-29","accession":"0000012208-22-000026","full_text":"https://origin.rootz.global/static/filing/0000012208-22-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":70,"context":"rding Michael Crowley, Ilan Daskal, Timothy S. Ernst, Dara Grantham Wright, Ronald W. Hutton, Andrew J. Last, Simon May, and Annette Tumolo is set forth below. **MICHAEL CROWLEY** Michael Crowley was appointed Executive Vice President, Global Commercial Operations in December 2014. Previously he was Vice&#xa0;President, Commercial Manager, Europe from 2012 to 2014 and Commercial Manager, Clinical Diagnostics Group, Europe from 201","filed_date":"2022-03-30","accession":"0001308179-22-000148","full_text":"https://origin.rootz.global/static/filing/0001308179-22-000148.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":20,"context":"reimbursement for our products or diagnostic tests using our products, or a decision by a third-party payor to not cover our products could reduce or eliminate utilization of our products and have a material adverse effect on our sales, results of operations and financial condition. In addition, healthcare reform measures have been and will be adopted in the future, any of which could limit the amounts that governments","filed_date":"2022-02-11","accession":"0000012208-22-000011","full_text":"https://origin.rootz.global/static/filing/0000012208-22-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":28,"context":"ranties contained in Article V of the Credit Agreement (as amended hereby) are true and correct in all material respects (or, in the case of any representation or warranty qualified by materiality or Material Adverse Effect, in all respects), except to the extent any such representation or warranty is stated to relate solely to an earlier date, in which case such representation or warranty was true and correct in all ma","filed_date":"2021-11-18","accession":"0001193125-21-333913","full_text":"https://origin.rootz.global/static/filing/0001193125-21-333913.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2021-10-29","accession":"0000012208-21-000050","full_text":"https://origin.rootz.global/static/filing/0000012208-21-000050.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2021-07-30","accession":"0000012208-21-000039","full_text":"https://origin.rootz.global/static/filing/0000012208-21-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":18,"context":"ing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2021-04-30","accession":"0000012208-21-000024","full_text":"https://origin.rootz.global/static/filing/0000012208-21-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":70,"context":"Michael Crowley, Ilan Daskal, Timothy S. Ernst, Dara Grantham Wright, Ronald W. Hutton, Andrew J. Last, Giovanni Magni, and Annette Tumolo is set forth below. **MICHAEL CROWLEY** Michael Crowley was appointed Executive Vice President, Global Commercial Operations in December 2014. Previously he was Vice President, Commercial Manager, Europe from 2012 to 2014 and Commercial Manager, Clinical Diagnostics Group, Europe from 2011 to","filed_date":"2021-03-31","accession":"0001308179-21-000130","full_text":"https://origin.rootz.global/static/filing/0001308179-21-000130.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":27,"context":"ecorded an $11.7 million gain in Other income, net, in the consolidated statements of income for the year ended December31, 2020. 27 Restructurings On February 3, 2021, we initiated a strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacts our operations in Europe and includes the elimination of certain positions, the consol","filed_date":"2021-02-16","accession":"0000012208-21-000012","full_text":"https://origin.rootz.global/static/filing/0000012208-21-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":27,"context":"reimbursement for our products or diagnostic tests using our products, or a decision by a third-party payor to not cover our products could reduce or eliminate utilization of our products and have a material adverse effect on our sales, results of operations and financial condition. In addition, healthcare reform measures have been and will be adopted in the future, any of which could limit the amounts that governments","filed_date":"2021-02-16","accession":"0000012208-21-000012","full_text":"https://origin.rootz.global/static/filing/0000012208-21-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":12,"context":"nt to Section 13(a) of the Exchange Act. |  ITEM2.05 |  Costs Associated with Exit or Disposal Activities. | | On February3, 2021, Bio-Rad Laboratories, Inc. (the Company) initiated a strategy-driven restructuring plan in furtherance of the Companys ongoing program to improve operating performance. The restructuring plan primarily impacts our operations in Europe and includes the elimination of certain positions, t","filed_date":"2021-02-04","accession":"0001193125-21-027959","full_text":"https://origin.rootz.global/static/filing/0001193125-21-027959.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":12,"context":"regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period. 33 13.RESTRUCTURING COSTS In December 2018, we announced the closure of a small manufacturing facility in France. Restructuring charges for the facility closure are included in our Clinical Diagnostics segment's results of op","filed_date":"2020-10-30","accession":"0000012208-20-000055","full_text":"https://origin.rootz.global/static/filing/0000012208-20-000055.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":24,"context":"ing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2020-10-30","accession":"0000012208-20-000055","full_text":"https://origin.rootz.global/static/filing/0000012208-20-000055.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":12,"context":"ce regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period. 13.RESTRUCTURING COSTS In December 2018, we announced the closure of a small manufacturing facility outside Paris, France. From December 2018 to June30, 2020, total expenses were $4.0 million. Restructuring charges for the","filed_date":"2020-07-31","accession":"0000012208-20-000039","full_text":"https://origin.rootz.global/static/filing/0000012208-20-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":25,"context":"ing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2020-07-31","accession":"0000012208-20-000039","full_text":"https://origin.rootz.global/static/filing/0000012208-20-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":13,"context":"ce regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period. 13.RESTRUCTURING COSTS Restructuring Costs for a Facility Closure In December 2018, we announced the closure of a small manufacturing facility outside Paris, France. From December 2018 to March31, 2020, total expenses were","filed_date":"2020-05-08","accession":"0000012208-20-000022","full_text":"https://origin.rootz.global/static/filing/0000012208-20-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":24,"context":"ing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2020-05-08","accession":"0000012208-20-000022","full_text":"https://origin.rootz.global/static/filing/0000012208-20-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":75,"context":"0 |  |  113,000 | | **Advisory (Non-Binding) Vote to Approve Executive Compensation (page 19)** We are asking our stockholders to cast a non-binding advisory vote to approve the compensation of our named executive officers. BIO-RAD LABORATORIES, INC. - *2020 Proxy Statement ** *5 [Back to Contents](#toc) Proxy Statement 2020 ANNUAL MEETING Our Board of Directors is soliciting the enclosed proxy in connection with our","filed_date":"2020-04-01","accession":"0001308179-20-000115","full_text":"https://origin.rootz.global/static/filing/0001308179-20-000115.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":31,"context":"e believe that the acquisition will expand our reagents suite of offerings in our Life Science operations. The above acquisitions are immaterial to Bio-Rad taken as a whole for the periods presented. Restructuring Costs for European and North American Reorganization In November 2019, we announced our strategy-driven restructuring plan. We expect that a significant portion of the net savings resulting from this restr","filed_date":"2020-03-02","accession":"0000012208-20-000012","full_text":"https://origin.rootz.global/static/filing/0000012208-20-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":26,"context":"reimbursement for our products or diagnostic tests using our products, or a decision by a third-party payor to not cover our products could reduce or eliminate utilization of our products and have a material adverse effect on our sales, results of operations and financial condition. In addition, healthcare reform measures have been and will be adopted in the future, any of which could limit the amounts that governments","filed_date":"2020-03-02","accession":"0000012208-20-000012","full_text":"https://origin.rootz.global/static/filing/0000012208-20-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":14,"context":"ing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2019-11-01","accession":"0001628280-19-013083","full_text":"https://origin.rootz.global/static/filing/0001628280-19-013083.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":10,"context":"regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period. 29 13.RESTRUCTURING COSTS Restructuring Costs for European Reorganization In May, 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gros","filed_date":"2019-08-06","accession":"0000012208-19-000054","full_text":"https://origin.rootz.global/static/filing/0000012208-19-000054.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":14,"context":"ing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2019-08-06","accession":"0000012208-19-000054","full_text":"https://origin.rootz.global/static/filing/0000012208-19-000054.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":13,"context":"ing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operation","filed_date":"2019-05-10","accession":"0000012208-19-000044","full_text":"https://origin.rootz.global/static/filing/0000012208-19-000044.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":26,"context":"(B) hereof.  Loan Modification Offer is defined in Section 2.24(A) hereof.  Loan Parties means the Borrower and each Guarantor.  Margin Stock shall have the meaning assigned thereto in Regulation U.  Material Adverse Effect means a material adverse effect on (i) the business, Property, financial condition or results of operations of the Borrower and its Subsidiaries taken as a whole, (ii) the ability of the Borrower and","filed_date":"2019-04-16","accession":"0001193125-19-107923","full_text":"https://origin.rootz.global/static/filing/0001193125-19-107923.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":67,"context":"ective April 6, 2019 Ilan Daskal, Timothy S. Ernst, John Hertia, Ronald W. Hutton, Giovanni Magni, Christine A. Tsingos and Annette Tumolo is set forth below. ***MICHAEL CROWLEY** Michael Crowley was appointed Executive Vice President, Global Commercial Operations in December 2014. Previously he was Vice President, Commercial Manager, Europe from 2012 to 2014 and Commercial Manager, Clinical Diagnostics Group, Europe from 2011 to","filed_date":"2019-04-04","accession":"0001308179-19-000113","full_text":"https://origin.rootz.global/static/filing/0001308179-19-000113.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":24,"context":"respectively, associated with the 2014 acquisition of GnuBIO, Inc. Also in 2016, we impaired an intellectual property license associated with a research and development project for $2.4 million.  26 Restructuring Costs for Termination of a Diagnostics Research and Development Project and Facility Closures In December 2018, we announced the closure of a small manufacturing facility outside Paris, France. We recorded","filed_date":"2019-04-01","accession":"0000012208-19-000014","full_text":"https://origin.rootz.global/static/filing/0000012208-19-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":15,"context":"reimbursement for our products or diagnostic tests using our products, or a decision by a third-party payor to not cover our products could reduce or eliminate utilization of our products and have a material adverse effect on our sales, results of operations and financial condition. In addition, healthcare reform measures have been and will be adopted in the future, any of which could limit the amounts that governments","filed_date":"2019-04-01","accession":"0000012208-19-000014","full_text":"https://origin.rootz.global/static/filing/0000012208-19-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BIO","company":"BIO-RAD LABORATORIES, INC.","exchange":"NYSE","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":9,"context":"regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period. 27 12.RESTRUCTURING COSTS Restructuring Costs for European Reorganization In May, 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gros","filed_date":"2018-11-05","accession":"0000012208-18-000048","full_text":"https://origin.rootz.global/static/filing/0000012208-18-000048.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"4c2f705adf795a706371c8c6107f341d31dfb5f2e01b7b2a57fe4b2de4188610","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"84e54742b2007ed12d252e6a910c661f388bf50311de13dd64722085de1d58b5","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":67,"hourly_limit":500,"remaining":433,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}